Relay Therapeutics (RLAY) risk factors
Item 1A of every Relay Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors87 risks10 new8 dropped19 reworded
Relay Therapeutics highlights clinical side effects for combination therapies and new FDA companion diagnostic requirements for zovegalisib. The company expands risks regarding reliance on third-party manufacturers, intellectual property challenges, and cybersecurity compliance under Massachusetts regulations. Regulatory pathways such as RTOR are noted as providing no guarantee of faster approval.
Filed Feb 26, 2026 - FY2024 10-K risk factors85 risks
Relay Therapeutics has a cumulative deficit of $1.7 billion as of December 31, 2024, with net losses of $337.7 million in 2024. The company relies entirely on single-source suppliers for active pharmaceutical ingredients and has preclinical programs in vascular malformations, Fabry disease, and NRAS. Lead candidate RLY-2608 and others are developed using novel mechanisms of action and structure-based drug design.
Filed Feb 26, 2025